A detailed history of Bank Of Montreal transactions in Profound Medical Corp. stock. As of the latest transaction made, Bank Of Montreal holds 14,247 shares of PROF stock, worth $114,118. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,247
Previous 11,670 22.08%
Holding current value
$114,118
Previous $97,000 16.49%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$7.47 - $11.18 $19,250 - $28,810
2,577 Added 22.08%
14,247 $113,000
Q2 2024

Aug 14, 2024

BUY
$7.25 - $9.07 $978 - $1,224
135 Added 1.17%
11,670 $97,000
Q1 2024

May 13, 2024

SELL
$7.3 - $9.46 $3,058 - $3,963
-419 Reduced 3.51%
11,535 $98,000
Q4 2023

Feb 08, 2024

SELL
$7.85 - $11.18 $730 - $1,039
-93 Reduced 0.77%
11,954 $101,000
Q3 2023

Nov 01, 2023

SELL
$7.91 - $13.27 $189 - $318
-24 Reduced 0.2%
12,047 $122,000
Q2 2023

Aug 02, 2023

SELL
$9.27 - $14.88 $210,614 - $338,073
-22,720 Reduced 65.3%
12,071 $157,000
Q1 2023

Jun 13, 2024

BUY
$8.85 - $13.27 $7,982 - $11,969
902 Added 7.82%
12,437 $115,000
Q4 2022

Feb 01, 2023

BUY
$3.18 - $10.91 $384 - $1,320
121 Added 0.35%
34,791 $378,000
Q3 2022

Nov 10, 2022

BUY
$3.99 - $9.3 $9,763 - $22,757
2,447 Added 7.59%
34,670 $174,000
Q2 2022

Aug 11, 2022

SELL
$6.34 - $9.53 $7,316 - $10,997
-1,154 Reduced 3.46%
32,223 $280,000
Q1 2022

May 12, 2022

BUY
$8.16 - $11.33 $2,064 - $2,866
253 Added 0.76%
33,377 $318,000
Q4 2021

Feb 11, 2022

BUY
$10.38 - $15.2 $42,516 - $62,259
4,096 Added 14.11%
33,124 $395,000
Q3 2021

Nov 12, 2021

SELL
$13.6 - $17.88 $532,358 - $699,894
-39,144 Reduced 57.42%
29,028 $451,000
Q2 2021

Aug 12, 2021

BUY
$16.0 - $20.59 $1.09 Million - $1.4 Million
68,172 New
68,172 $1.22 Million

Others Institutions Holding PROF

About Profound Medical Corp.


  • Ticker PROF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 20,851,300
  • Market Cap $167M
  • Description
  • Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for...
More about PROF
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.